Inventor · disambiguated record
Stephen Marcus
Also filed as: MARCUS STEPHEN · MARCUS STEPHEN G
7 granted patents·13 pending applications·15 citations·filing 2012–2023
80Inventor score
Top patents by PatentIndex Score
20 records- 0188US10052346B2Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoidsCANTEX PHARMACEUTICALS INC·Filed 2016·Granted Aug 21, 2018·4 cites·19 claims
- 0287US11648235B1Treatment of glioblastomaCANTEX PHARMACEUTICALS INC·Filed 2022·Granted May 16, 2023·1 cites·30 claims
- 0383US8734804B2Treatment of myelosuppressionPARINGENIX INC·Filed 2013·Granted May 27, 2014·6 cites·30 claims
- 0480US9271999B2Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2013·Granted Mar 1, 2016·4 cites·22 claims
- 0574US11229664B2Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2019·Granted Jan 25, 2022·0 cites·20 claims
- 0674US2022354882A1Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0771US2022054531A1Treatment of acute myeloid leukemia with hypomethylating agents and 2-o, 3-o desulfated heparinoidsCANTEX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0870US10905661B2Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage formsCANTEX PHARMACEUTICALS INC·Filed 2019·Granted Feb 2, 2021·0 cites·18 claims
- 0967US2024216333A1Treatment of glioblastomaCANTEX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1066US10322096B2Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage formsCANTEX PHARMACEUTICALS INC·Filed 2017·Granted Jun 18, 2019·0 cites·2 claims
- 1166US2019015443A1Treatment of myelodysplastic syndromes with 2-o and, or 3-o desulfated heparinoidsCANTEX PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1264US2020237803A1Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interactionCANTEX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1362US2020397726A1Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage formsCANTEX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1460US2018296590A1Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1554US2016213706A1Treatment of myelosuppressionCANTEX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1643US2012196828A1Sensitization of cancer cells to treatmentMARCUS STEPHEN·Filed 2012·Application pending·0 cites
- 1743US2016287626A1Methods of treating and preventing radiation damageCANTEX PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1841US2017106011A1Methods of treating traumatic brain injury and sequelaeCANTEX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1939US2016243168A1Adoptive cell transfer methodsCANTEX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2031US2017096549A1Multivalent cation formulations of partially desulfated heparinsCANTEX PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen Marcus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →